Abstracts tagged "pulmonary"

Abstract Number: 1108 • ACR Convergence 2022
Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor Associated Pneumonitis
Danielle Stahlbaum¹, Renea Jablonski¹, Mary Strek² and Pankti Reid¹, ¹University of Chicago Medical Center, Chicago, IL, ²University of Chicago, Chicago, IL
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in off-target toxicities known as immune-related adverse events (irAEs). With increased use of…
Abstract Number: 2176 • ACR Convergence 2022
Novel Tissue Turnover Blood Markers Are Associated with Pulmonary Arterial Hypertension and NYHA Stages in Patients with Systemic Sclerosis
Signe Holm Nielsen¹, Sine Søndergaard Korsholm², Axel Diederichsen³, Morten Karsdal¹, John Bonde Knudsen⁴, Anne-Christine Bay-Jensen¹, Louise Diederichsen⁵ and Christoffer Tandrup Nielsen⁶, ¹Nordic Bioscience, Herlev, Denmark, ²Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Dept of Rheumatology, Odense University Hospital (OUH), Odense, Denmark, ³Dept of Cardiology, OUH, Odense, Denmark, Odense, ⁴Dept of Rheumatology, OUH, Odense, Denmark., Odense, ⁵Copenhagen University Hospital, Rigshospitalet, Dragør, Denmark, ⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Systemic sclerosis (SSc) is characterized by vasculopathy and fibrosis of the skin and internal organs. Cardiac involvement, pulmonary arterial hypertension (PAH), and interstitial lung…
Abstract Number: 0075 • ACR Convergence 2022
Real-World Treatment Patterns Among Patients with Connective Tissue Disorder–Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis
Yuen Tsang¹, Marjolaine Gauthier-Loiselle², Vienica Funtanilla³, Hayley Germack³, Ameur Manceur⁴, Stephanie Liu², Martin Cloutier², Patrick Lefebvre² and Sumeet Panjabi⁵, ¹Janssen Scientific Affairs, LLC., Sacramento, CA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Janssen Scientific Affairs, LLC, Titusville, NJ, ⁴Analysis Group, Inc, Boston, MA, ⁵Analysis Group, Inc., Titusville, NB, Canada
Background/Purpose: Connective tissue disorders (CTDs) are the most frequent diseases associated with pulmonary arterial hypertension (PAH), accounting for 11% – 28% of PAH cases. A…
Abstract Number: 1110 • ACR Convergence 2022
Solving Sarcoidosis: A Transcriptome-based Meta-analysis of Clinical Sarcoidosis Studies Illustrates Shared Pathophysiology, Identifies Candidate Biomarkers and Suggests a Therapeutic Mechanism of JAK Inhibition
Ingrid Lindquist¹, James T. Rosenbaum² and Marcia Friedman³, ¹Oregon Health and Science University, Portland, OR, ²Legacy Devers Eye Institute, Portland, OR, ³Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR
Background/Purpose: Sarcoidosis is a systemic, non-caseating granulomatous disease driven by a dysregulated immune response to environmental antigens. A wide range of clinical manifestations coupled with…
Abstract Number: 0124 • ACR Convergence 2022
Evaluation of Comorbidity Burden and Its Effect on Lung Disease Progression and Mortality in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
Elena Joerns¹, Michelle Ghebranious¹, Traci Adams¹ and Una Makris², ¹UT Southwestern, Dallas, TX, ²UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) which manifests with interstitial pneumonia and features of autoimmunity, yet…
Abstract Number: 1282 • ACR Convergence 2022
Practice Patterns for Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Among Nephrologists and Rheumatologists – an International Survey Study
Swati Arora¹, Brad Rovin² and Tanmayee Bichile³, ¹Allegheny Health Network, Pittsburgh, ²The Ohio State University, Columbus, OH, ³Allegheny Health Network, Gibsonia, PA
Background/Purpose: Patients with autoimmune disorders such as systemic lupus erythematosus (SLE), lupus nephritis (LN) and granulomatosis with polyangiitis (GPA) frequently require treatment with immunosuppressive drugs.…
Abstract Number: 0140 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Müller⁶, Carl Coeck⁷, Klaus Rohr⁸ and Wim Wuyts⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁷Boehringer Ingelheim SComm, Brussels, Brussels, Belgium, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital…
Abstract Number: 1325 • ACR Convergence 2022
The Risks of Osteoporotic Fracture After Lung Transplant: A Retrospective Cohort Study at an International Transplant Center
Adil Vural¹, Sarah Keller², Neel Tapryal³, Komal Mushtaq⁴, Hassan Shaheen¹, Chao Zhang², Marie Budev², Abby Abelson² and Chad Deal⁵, ¹Cleveland Clinic, Westlake, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Rocky River, OH, ⁴Cleveland Clinic, Fairview Park, OH, ⁵Cleveland Clinic, Shaker Heights, OH
Background/Purpose: Osteoporotic fractures are a well-known complication of lung transplant (LT) and can significantly impact the quality of life of LT recipients. Although much is…
Abstract Number: 0191 • ACR Convergence 2022
Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties
Jacqueline Lemmers¹, Madelon Vonk² and Els Ende, van den³, ¹Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Radboudumc, Nijmegen, Netherlands
Background/Purpose: This COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN)-based systematic review aims to identify and summarize the quality of measurement properties of…
Abstract Number: 1524 • ACR Convergence 2022
Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort
Ahmad Ramahi¹, Alain Lescoat², David Roofeh¹, Vivek Nagaraja¹, Rajaie Namas³, Suiyuan Huang¹, John Varga¹, David O’Dwyer¹, Bonnie Wang¹, Kevin Flaherty¹, Ella Kazerooni¹ and Dinesh Khanna⁴, ¹University of Michigan, Ann Arbor, MI, ²CHU Rennes - University Rennes 1, Rennes, France, ³Medical Subspecialties Institute, Division of Rheumatology at Cleveland Clinic, Abu Dhabi, United Arab Emirates, ⁴Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of scleroderma-related mortality. This work identifies factors associated with SSc-ILD decline on pulmonary function…
Abstract Number: 0258 • ACR Convergence 2022
Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents
Sascha Heckert¹, Tjardo Maarseveen², Emiel Marges², Arvind Chopra³, David Vega Morales⁴, Riette Du Toit⁵, Annette van der Helm-van Mil⁶, Tom Huizinga², CF Allaart² and Sytske Anne Bergstra⁷, ¹Leiden University Medical Centre, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Center for Rheumatic Diseases, Pune, Maharashtra, India, ⁴Hospital General de Zona 17, Instituto Mexicano del Seguro Social, Monterrey, Mexico, ⁵Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa, ⁶Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, ⁷LUMC, Leiden, Netherlands
Background/Purpose: Interstitial lung disease (ILD) is a spectrum of inflammatory and fibrotic lung diseases, and can be associated with RA (RA-ILD). The reported prevalence in…
Abstract Number: 1531 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON
Yannick Allanore¹, Madelon Vonk², Oliver Distler³, Arata Azuma⁴, Maureen Mayes⁵, Alexandra James⁶, Veronika Kohlbrenner⁷, Margarida Alves⁸, Dinesh Khanna⁹ and Kristin Highland¹⁰, ¹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶Elderbrook solutions GmbH, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁰Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH
Background/Purpose: In the randomized placebo-controlled SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52…
Abstract Number: 0438 • ACR Convergence 2022
Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies
Khai-Tuan Andrew Bui¹, Rachel Richard², Ariane Drouin³, Nader Toban¹, Marianne Levesque⁴, Rosalie-Selene Meunier⁵, Carolyn Ross⁶ and Jean-Paul Makhzoum³, ¹Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ²Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Laval, QC, Canada, ³Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ⁴Division of Respirology, Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ⁵Hopital Sacre-Coeur, Universite de Montreal, Montréal, QC, Canada, ⁶University of Montreal, Montréal, QC, Canada
Background/Purpose: Various pulmonary manifestations may occur in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). ANCA-related interstitial lung disease (ILD) has recently been described in…
Abstract Number: 1622 • ACR Convergence 2022
TNF Receptor 1 Drives Murine Pulmonary Arterial Hypertension and Is Characterized by Loss of Capillary Endothelial Cells and Pericytes, Smooth Muscle Cell Proliferation, and Alterations in Fibroblast Phenotype
Stacey Duemmel¹, Marc Nuzzo¹, Soumyaroop Bhattacharya¹, Qingfu Xu¹, Amy Mohan¹ and Benjamin Korman², ¹URMC, Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: We previously demonstrated that TNF-transgenic (TNF-Tg) mice have findings consistent with connective-tissue disease associated pulmonary arterial hypertension (CTD-PAH), and that this pathology is mediated…
Abstract Number: 0533 • ACR Convergence 2022
Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity
Timothy Wilson¹, Jacob Welch², Marie Feser², Elizabeth Bemis², Claudia Lugo², Gary S. Firestein³, Thomas F. Bumol⁴, Jill Norris⁵, V. Michael Holers⁶, Kevin D Deane⁷ and Kristen Demoruelle², ¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of California, San Diego, San Diego, CA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Aurora, CO, ⁶University of Colorado, Denver, CO, ⁷University of Colorado Denver Anschutz Medical Campus, Denver, CO
Background/Purpose: Presence of systemic anti-CCP-IgG antibodies in individuals without inflammatory arthritis (IA) strongly predicts developing future classified RA. However, published data also demonstrate that 50-70%…

« Previous Page
1
…
8
9
10
11
12
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].